Long-term benefit of the TAXUS liberté stent in small vessels and long lesions - TAXUS ATLAS program

John A. Ormiston, Mark A. Turco, Jack J. Hall, Louis A. Cannon, Steven J. Yakubov, Michael J. Lucca, Gregg W. Stone, Charles D. O'Shaughnessy, Joseph A. Kozina, Ian Gilchrist, Barry D. Bertolet, Stephen G. Worthley, Paul L. Underwood, Keith D. Dawkins

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: The long-term impact of treating de novo coronary lesions in native vessels and challenging small vessel and long lesion subsets with TAXUS Liberté stents is unknown. This report examines the 3-year efficacy and safety from the TAXUS ATLAS program. Methods and Results: TAXUS ATLAS WH, Small Vessel, and Long Lesion are non-randomized studies comparing TAXUS Liberté (n=871), TAXUS Liberté 2.25 mm (n=261), and TAXUS Liberté 38 mm (n=150) stents, respectively, to case-matched TAXUS Express historical controls. TAXUS Liberté demonstrated comparable 3-year rates of major adverse cardiac events (19.0% vs. 20.2%, P=0.51) in de novo lesions, reduced target lesion revascularization (TLR, 10.0% vs. 22.1%, P=0.008) in small vessels, and reduced myocardial infarction (MI, 2.9% vs. 10.4%; P=0.01) and stent thrombosis (ST, 0.0% vs. 3.9%, P=0.03) in long lesions vs. TAXUS Express. After propensity score adjustment, no statistically significant effect of TAXUS Liberté on TLR (9.7% vs. 16.9%, P=0.12) in small vessels or MI (2.9% vs. 7.9%, P=0.05) in long lesions was noted, although reduced ST (0.0% vs. 2.7%, P=0.02) remained in long lesions. Multivariate analyses demonstrated that TAXUS Liberté treatment significantly reduced TLR by 66% in small vessels, and MI by 75% in long lesions, vs. TAXUS Express. Conclusions: TAXUS Liberté suggests durable 3-year effectiveness in reducing restenosis and improved clinical outcomes in small vessels and long lesions compared with TAXUS Express.

Original languageEnglish (US)
Pages (from-to)1120-1129
Number of pages10
JournalCirculation Journal
Volume75
Issue number5
DOIs
StatePublished - May 1 2011

Fingerprint

Stents
Propensity Score
Thrombosis
Multivariate Analysis
Myocardial Infarction
Safety

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Ormiston, J. A., Turco, M. A., Hall, J. J., Cannon, L. A., Yakubov, S. J., Lucca, M. J., ... Dawkins, K. D. (2011). Long-term benefit of the TAXUS liberté stent in small vessels and long lesions - TAXUS ATLAS program. Circulation Journal, 75(5), 1120-1129. https://doi.org/10.1253/circj.CJ-10-0848
Ormiston, John A. ; Turco, Mark A. ; Hall, Jack J. ; Cannon, Louis A. ; Yakubov, Steven J. ; Lucca, Michael J. ; Stone, Gregg W. ; O'Shaughnessy, Charles D. ; Kozina, Joseph A. ; Gilchrist, Ian ; Bertolet, Barry D. ; Worthley, Stephen G. ; Underwood, Paul L. ; Dawkins, Keith D. / Long-term benefit of the TAXUS liberté stent in small vessels and long lesions - TAXUS ATLAS program. In: Circulation Journal. 2011 ; Vol. 75, No. 5. pp. 1120-1129.
@article{f5373761b2f5413da3976ce5c2292fff,
title = "Long-term benefit of the TAXUS libert{\'e} stent in small vessels and long lesions - TAXUS ATLAS program",
abstract = "Background: The long-term impact of treating de novo coronary lesions in native vessels and challenging small vessel and long lesion subsets with TAXUS Libert{\'e} stents is unknown. This report examines the 3-year efficacy and safety from the TAXUS ATLAS program. Methods and Results: TAXUS ATLAS WH, Small Vessel, and Long Lesion are non-randomized studies comparing TAXUS Libert{\'e} (n=871), TAXUS Libert{\'e} 2.25 mm (n=261), and TAXUS Libert{\'e} 38 mm (n=150) stents, respectively, to case-matched TAXUS Express historical controls. TAXUS Libert{\'e} demonstrated comparable 3-year rates of major adverse cardiac events (19.0{\%} vs. 20.2{\%}, P=0.51) in de novo lesions, reduced target lesion revascularization (TLR, 10.0{\%} vs. 22.1{\%}, P=0.008) in small vessels, and reduced myocardial infarction (MI, 2.9{\%} vs. 10.4{\%}; P=0.01) and stent thrombosis (ST, 0.0{\%} vs. 3.9{\%}, P=0.03) in long lesions vs. TAXUS Express. After propensity score adjustment, no statistically significant effect of TAXUS Libert{\'e} on TLR (9.7{\%} vs. 16.9{\%}, P=0.12) in small vessels or MI (2.9{\%} vs. 7.9{\%}, P=0.05) in long lesions was noted, although reduced ST (0.0{\%} vs. 2.7{\%}, P=0.02) remained in long lesions. Multivariate analyses demonstrated that TAXUS Libert{\'e} treatment significantly reduced TLR by 66{\%} in small vessels, and MI by 75{\%} in long lesions, vs. TAXUS Express. Conclusions: TAXUS Libert{\'e} suggests durable 3-year effectiveness in reducing restenosis and improved clinical outcomes in small vessels and long lesions compared with TAXUS Express.",
author = "Ormiston, {John A.} and Turco, {Mark A.} and Hall, {Jack J.} and Cannon, {Louis A.} and Yakubov, {Steven J.} and Lucca, {Michael J.} and Stone, {Gregg W.} and O'Shaughnessy, {Charles D.} and Kozina, {Joseph A.} and Ian Gilchrist and Bertolet, {Barry D.} and Worthley, {Stephen G.} and Underwood, {Paul L.} and Dawkins, {Keith D.}",
year = "2011",
month = "5",
day = "1",
doi = "10.1253/circj.CJ-10-0848",
language = "English (US)",
volume = "75",
pages = "1120--1129",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "5",

}

Ormiston, JA, Turco, MA, Hall, JJ, Cannon, LA, Yakubov, SJ, Lucca, MJ, Stone, GW, O'Shaughnessy, CD, Kozina, JA, Gilchrist, I, Bertolet, BD, Worthley, SG, Underwood, PL & Dawkins, KD 2011, 'Long-term benefit of the TAXUS liberté stent in small vessels and long lesions - TAXUS ATLAS program', Circulation Journal, vol. 75, no. 5, pp. 1120-1129. https://doi.org/10.1253/circj.CJ-10-0848

Long-term benefit of the TAXUS liberté stent in small vessels and long lesions - TAXUS ATLAS program. / Ormiston, John A.; Turco, Mark A.; Hall, Jack J.; Cannon, Louis A.; Yakubov, Steven J.; Lucca, Michael J.; Stone, Gregg W.; O'Shaughnessy, Charles D.; Kozina, Joseph A.; Gilchrist, Ian; Bertolet, Barry D.; Worthley, Stephen G.; Underwood, Paul L.; Dawkins, Keith D.

In: Circulation Journal, Vol. 75, No. 5, 01.05.2011, p. 1120-1129.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term benefit of the TAXUS liberté stent in small vessels and long lesions - TAXUS ATLAS program

AU - Ormiston, John A.

AU - Turco, Mark A.

AU - Hall, Jack J.

AU - Cannon, Louis A.

AU - Yakubov, Steven J.

AU - Lucca, Michael J.

AU - Stone, Gregg W.

AU - O'Shaughnessy, Charles D.

AU - Kozina, Joseph A.

AU - Gilchrist, Ian

AU - Bertolet, Barry D.

AU - Worthley, Stephen G.

AU - Underwood, Paul L.

AU - Dawkins, Keith D.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Background: The long-term impact of treating de novo coronary lesions in native vessels and challenging small vessel and long lesion subsets with TAXUS Liberté stents is unknown. This report examines the 3-year efficacy and safety from the TAXUS ATLAS program. Methods and Results: TAXUS ATLAS WH, Small Vessel, and Long Lesion are non-randomized studies comparing TAXUS Liberté (n=871), TAXUS Liberté 2.25 mm (n=261), and TAXUS Liberté 38 mm (n=150) stents, respectively, to case-matched TAXUS Express historical controls. TAXUS Liberté demonstrated comparable 3-year rates of major adverse cardiac events (19.0% vs. 20.2%, P=0.51) in de novo lesions, reduced target lesion revascularization (TLR, 10.0% vs. 22.1%, P=0.008) in small vessels, and reduced myocardial infarction (MI, 2.9% vs. 10.4%; P=0.01) and stent thrombosis (ST, 0.0% vs. 3.9%, P=0.03) in long lesions vs. TAXUS Express. After propensity score adjustment, no statistically significant effect of TAXUS Liberté on TLR (9.7% vs. 16.9%, P=0.12) in small vessels or MI (2.9% vs. 7.9%, P=0.05) in long lesions was noted, although reduced ST (0.0% vs. 2.7%, P=0.02) remained in long lesions. Multivariate analyses demonstrated that TAXUS Liberté treatment significantly reduced TLR by 66% in small vessels, and MI by 75% in long lesions, vs. TAXUS Express. Conclusions: TAXUS Liberté suggests durable 3-year effectiveness in reducing restenosis and improved clinical outcomes in small vessels and long lesions compared with TAXUS Express.

AB - Background: The long-term impact of treating de novo coronary lesions in native vessels and challenging small vessel and long lesion subsets with TAXUS Liberté stents is unknown. This report examines the 3-year efficacy and safety from the TAXUS ATLAS program. Methods and Results: TAXUS ATLAS WH, Small Vessel, and Long Lesion are non-randomized studies comparing TAXUS Liberté (n=871), TAXUS Liberté 2.25 mm (n=261), and TAXUS Liberté 38 mm (n=150) stents, respectively, to case-matched TAXUS Express historical controls. TAXUS Liberté demonstrated comparable 3-year rates of major adverse cardiac events (19.0% vs. 20.2%, P=0.51) in de novo lesions, reduced target lesion revascularization (TLR, 10.0% vs. 22.1%, P=0.008) in small vessels, and reduced myocardial infarction (MI, 2.9% vs. 10.4%; P=0.01) and stent thrombosis (ST, 0.0% vs. 3.9%, P=0.03) in long lesions vs. TAXUS Express. After propensity score adjustment, no statistically significant effect of TAXUS Liberté on TLR (9.7% vs. 16.9%, P=0.12) in small vessels or MI (2.9% vs. 7.9%, P=0.05) in long lesions was noted, although reduced ST (0.0% vs. 2.7%, P=0.02) remained in long lesions. Multivariate analyses demonstrated that TAXUS Liberté treatment significantly reduced TLR by 66% in small vessels, and MI by 75% in long lesions, vs. TAXUS Express. Conclusions: TAXUS Liberté suggests durable 3-year effectiveness in reducing restenosis and improved clinical outcomes in small vessels and long lesions compared with TAXUS Express.

UR - http://www.scopus.com/inward/record.url?scp=79955702491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955702491&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-10-0848

DO - 10.1253/circj.CJ-10-0848

M3 - Article

C2 - 21467655

AN - SCOPUS:79955702491

VL - 75

SP - 1120

EP - 1129

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 5

ER -